FDA CRL Analysis
Deficiency patterns from 291 FDA Complete Response Letters — sorted by submission type, root cause, and module. What actually triggers CRLs and what most teams miss.
291 letters analyzed
Resources
Regulatory Resources & Guides
Explore Assyro's live glossary and reference content, with additional checklists, pathway guides, and comparison tools staged for release.
Regulatory Glossary
Comprehensive definitions of regulatory terms, acronyms, and concepts used in pharmaceutical, biotech, and medical device industries.
153 termsSubmission Templates
Submission-ready document templates for IND, NDA, BLA, ANDA, 510(k), and eCTD Module 1-5 dossiers, pre-structured to FDA and ICH CTD expectations.
6 template familiesSubmission Checklists
Step-by-step readiness checklists for IND-enabling, NDA/BLA filing, 510(k) substantial-equivalence, eCTD validation pre-lock, and agency-response workflows.
5 checklistsRegulatory Pathways
Detailed guides for NDA, ANDA, BLA, IND, 510(k), PMA, De Novo, and other regulatory submission pathways.
Coming soonComparisons
Side-by-side comparisons of regulatory agencies, submission types, and pathway requirements.
Coming soon